BradyBlaze Posted - 20 hours ago

all my favorite stocks is moving $NDRA $NLSP $MYNZ 🚀🚀🚀

BriellaHowell__ Posted - 21 hours ago

$NIO $NLSP $CNSP 🔬📰👌

Bigdogsareus Posted - 1 day ago

$NLSP adding every dip

Tom1985IT Posted - 2 days ago

@Khockey11 orexin are the future, if approved and successful in also treating cataplexy they could replace sodium oxybate. $NLSP has the only dual orexin agonist currently in development.

Tom1985IT Posted - 2 days ago

$NLSP loading zone!

Tom1985IT Posted - 3 days ago

$NLSP interesting catalyst to be played in the next few weeks.

DonCorleone77 Posted - 3 days ago

$NLSP NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 NLS Pharmaceutics provided insights into the preclinical program evaluating its dual orexin receptor agonist platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed to target both orexin-1 and orexin-2 receptors while concurrently inhibiting cathepsins. This unique approach aims to address the unmet therapeutic needs in narcolepsy and related neurological disorders. The ongoing studies are conducted at the Centre for Neuroscience Research of Lyon, a world-class institution specializing in sleep and neurological research. The experimental framework is designed to explore the therapeutic potential of AEX compounds using an international validated orexin knockout mouse model of narcolepsy. Key elements of the study include: Study Objectives: Promote Wakefulness: Evaluate the impact of AEX compounds on maintaining wakefulness in narcoleptic mice. Enhance Sleep Quality: Assess improvements in sleep architecture and stability. Suppress Cataplexy Attacks: Measure reductions in the frequency and severity of cataplexy, a hallmark symptom of narcolepsy. Methodology: The study leverages cutting-edge EEG/EMG technology to monitor brain activity and muscle tone, providing precise data on wakefulness, non-rapid eye movement, and rapid eye movement sleep phases. Post-surgical recovery is followed by controlled drug administration, ensuring accurate measurement of the compound's efficacy. Robust Experimental Design: The study aims to evaluate the potential superiority of AEX compounds over existing therapies through a two-part approach: Part 1: Direct evaluation of AEX compounds performance on key metrics such as sustained wakefulness and improved sleep architecture. Part 2: Assessment of compound efficacy under challenging stress conditions, including sleep deprivation, to test the robustness and durability of their effects. While existing selective OX2R agonists have demonstrated efficacy in managing narcolepsy symptoms, DOXA are expected to surpass these benchmarks. By engaging both OX1R and OX2R receptors and addressing broader neurological pathways, AEX-41 and AEX-2 offer the potential for enhanced therapeutic outcomes, including greater wakefulness stability and improved sleep quality under real-world conditions. NLS remains committed to advancing its pipeline and anticipates providing further updates as the preclinical program progresses. First results from the ongoing study are expected to be shared in early December 2024.

Evilmarine Posted - 6 days ago

$NLSP adding 😊 wish me luck 🍀

TheFlash Posted - 6 days ago

$NLSP Merger play like $PULM which ran over 100% $2.00 to $7.87 👀

TheStockBeaver Posted - 1 week ago

$NLSP this company is pure ass. Bottom of the barrel garbage. Can’t believe I EVER thought it would be a good idea to jump into this piece of shit. If I could go back in time, I would beat the absolute piss out of myself for even laying eyes on the worthless , bullshit ticker

MS1974 Posted - 1 week ago

$MCRB Nice example of $NLSP, top results, exclusive rights to the product, at the end searching for a partnership, the takeover of some Israel companies and the destruction of shareholders...

cozi Posted - 1 week ago

$NLSP is and has been garbage

cozi Posted - 1 week ago

$NLSP loser

Leonidas_Knight Posted - 1 week ago

💥 Huge news expected for MYNZ soon 💥 Nov 12: 51M volume, +28%, with 19M short volume. With everyone awaiting the meeting results, I have a strong feeling the r/s extension will be pushed out another 180 days. Mainz Biomed (MYNZ) has partnered with Thermo Fisher (TMO, $209.2B market cap, trading at ~$546.92) to develop a next-gen colorectal cancer screening tool for global markets. Thermo Fisher’s $42.4B revenue and advanced tech will boost MYNZ’s mRNA-based assays, achieving 85% detection for advanced adenomas, compared to competitors' 43% and 20%. With CRC cases up 500% in young people, MYNZ is leading early detection. Sentiment: Positive 1. Strategic partnership with industry giant Thermo Fisher 2. Access to Thermo Fisher's advanced tech 3. Potential for global commercialization 4. Development of home collection screening capability Win-win as TMO steps into the CRC market, too. Calling all apes, let’s crush the short sellers—this bull run is ours. $NLSP $PLUG

Morgan_Johnson Posted - 1 week ago

💥 Huge news expected for MYNZ soon 💥 Nov 12: 51M volume, +28%, with 19M short volume. With everyone awaiting the meeting results, I have a strong feeling the r/s extension will be pushed out another 180 days. Mainz Biomed (MYNZ) has partnered with Thermo Fisher (TMO, $209.2B market cap, trading at ~$546.92) to develop a next-gen colorectal cancer screening tool for global markets. Thermo Fisher’s $42.4B revenue and advanced tech will boost MYNZ’s mRNA-based assays, achieving 85% detection for advanced adenomas, compared to competitors' 43% and 20%. With CRC cases up 500% in young people, MYNZ is leading early detection. Sentiment: Positive 1. Strategic partnership with industry giant Thermo Fisher 2. Access to Thermo Fisher's advanced tech 3. Potential for global commercialization 4. Development of home collection screening capability Win-win as TMO steps into the CRC market, too. Calling all apes, let’s crush the short sellers—this bull run is ours. $NLSP $PLUG

Axen7 Posted - 1 week ago

$NLSP boom

Axen7 Posted - 1 week ago

$NLSP doesn’t make sense that 10k shares can wipe away 2 million in market cap lol

Jhart55 Posted - 1 week ago

$NLSP I’ve been trying to put market sells in just to see and even the market sells won’t go through. Been sitting 10 minutes in que now.. what’s happening

HaltTradeAlert Posted - 1 week ago

$NLSP Halt Time: 09:38:27 Issue Symbol: NLSP Reason Code: LUDP Last Price: $3.18 Volume: 10.7 K Members get this halt alert with no delay and with more info: shares outstanding, market cap, relative volume, and percentage change on the day. Also, halt alerts for pre-market hours and after market hours which is extremely important for Code T1 News Pending Alerts!! And free real time news catalyst alerts!

rawful Posted - 1 week ago

$NLSP Halted?

Jpeices Posted - 1 week ago

$NLSP Hello all should I sell this or hold it ?

pepe202200 Posted - 1 week ago

$NLSP please do

ShortSqueeze10X Posted - 1 week ago

$NLSP $SONN

ShortSqueeze10X Posted - 1 week ago

$NLSP 👀👀

Diverter Posted - 1 week ago

$NLSP

ShortSqueeze10X Posted - 1 week ago

$NDRA $STAF $NLSP $SONN $LUCY Todays watchlist till noon 👀

TheStockBeaver Posted - 1 week ago

$NLSP I’ve been holding this shit for like 4 years and it hasn’t done dick this whole time. FUCK this stock

Axen7 Posted - 1 week ago

$NLSP someone’s keeping this low while then company that is merging with them has gone up 50% in 5 days. Hopefully that sentiment enters in here

Diverter Posted - 1 week ago

$NLSP 👀

Kira_Glass Posted - 1 week ago

MYNZ 🔥 Perfect time to jump in, cheapest dip!!! Shorts volume increased. HUGE PR drop incoming before the Nov 13 meeting, so compliance is coming, no RS needed. Here is why… 1.Frankie Muniz backing Mainz (yes, the Malcolm guy & NASCAR #33 now repping MYNZ). 2.Petra, ex-Obama advisor, hinted at a big U.S. lab partner. Solid source! 3.Six news hits in 3 weeks—momentum. 4.Already solid in the EU, not new but expanding, with insurance covering their tests. 5.Their test has 88% accuracy vs. EXAS (42%) & GH (20%)—big edge! 6.$1.5M private placement in the bag. 7.CEO teased big plans ahead. 8.Offering Deal $NLSP $PLUG